Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Biotechnology & Medical Research

Market Closed - Nasdaq 03:59:59 2024-03-28 pm EDT 5-day change 1st Jan Change
25.08 USD -0.16% Intraday chart for Mirum Pharmaceuticals, Inc. -7.08% -15.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
JMP Securities Raises Price Target on Mirum Pharmaceuticals to $72 From $69, Maintains Market Outperform Rating MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday MT
Sector Update: Health Care MT
HC Wainwright Adjusts Mirum Pharmaceuticals Price Target to $58 From $45, Maintain Buy Rating MT
Mirum Pharmaceuticals Says FDA Approved Familial Intrahepatic Cholestasis Treatment MT
Mirum Pharmaceuticals Gets Additional FDA Approval for Livmarli DJ
US FDA approves expanded use of Mirum's liver disease drug RE
Mirum Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approve LIVMARLI (Maralixibat) Oral Solution for the Treatment of Cholestatic Pruritus in Patients Five Years of Age and Older with Progressive Familial Intrahepatic Cholestasis CI
Cantor Fitzgerald Adjusts Price Target on Mirum Pharmaceuticals to $40 From $35, Maintains Overweight Rating MT
Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024 CI
Transcript : Mirum Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q4 Revenue $69.6M, vs. Street Est of $67.9M MT
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Mirum Pharmaceuticals, Inc. Announces Management Changes CI
Mirum Pharmaceuticals Names Joanne Quan as Chief Medical Officer MT
Mirum Pharmaceuticals, Inc. Announces Management Appointments CI
Transcript : Mirum Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM
Mirum Pharmaceuticals, Inc. Provides Earnings Guidance for Fourth Quarter 2023 and Full Year 2023 CI
Raymond James Cuts Price Target on Mirum Pharmaceuticals to $64 From $78, Keeps Strong Buy Rating MT
Sector Update: Health Care Stocks Rise in Late Afternoon MT
Sector Update: Health Care Stocks Rising Monday Afternoon MT
Mirum Pharmaceuticals Shares Fall After Disappointing Data From Phase 2B Study for Biliary Atresia MT
Mirum Pharma's liver disease therapy fails in mid-stage study RE
Mirum Pharmaceuticals, Inc. Announces Data from EMBARK Phase 2b Study for Biliary Atresia CI
Mirum Pharmaceuticals, Inc. Presents New Data at the Liver Meeting CI
Chart Mirum Pharmaceuticals, Inc.
More charts
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
25.12 USD
Average target price
49 USD
Spread / Average Target
+95.06%
Consensus